Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

American drug major AbbVie Healthcare’s Indian arm, which is under the scanner for sponsoring foreign trips of 30 doctors in violation of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP ...

The department of pharmaceuticals (DoP) reprimanded AbbVie Healthcare India for unethical marketing practices involving over ₹1 crore spent on foreign vacations for 30 doctors under the guise of ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other best stocks to buy and hold for 3 years. On December 12, Tom Lee, Fundstrat Global Advisors ...

The “Economic Loss Assistance Program” earmarks $10 billion in direct payments for farmers. While USDA will make the final calculations, Farm CPA Paul Neiffer estimates per acre producer ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE ... at least five of its programs will get regulatory approval.

AbbVie has a solid medium-term growth plan and ... In 2025, the company anticipates at least five of its programs will get regulatory approval. The next year after that could be just as good.